Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 13138Triple Negative Breast Neoplasms 1150Neoplasms 750Ovarian Neoplasms 680Neoplasm Metastasis 590Lung Neoplasms 582Colorectal Neoplasms 581Prostatic Neoplasms 560Carcinoma, Non-Small-Cell Lung 536Pancreatic Neoplasms 380Melanoma 366Stomach Neoplasms 350Colonic Neoplasms 330Motor Activity 285Breast Neoplasms, Male 285Carcinoma, Intraductal, Noninfiltrating 277Uterine Cervical Neoplasms 267Head and Neck Neoplasms 266Endometrial Neoplasms 256Carcinoma, Renal Cell 216Sarcoma 204Urinary Bladder Neoplasms 192Squamous Cell Carcinoma of Head and Neck 192Lymphedema 190Esophageal Neoplasms 189Breast Carcinoma In Situ 189Brain Neoplasms 183Fatigue 166Carcinoma, Ovarian Epithelial 151Small Cell Lung Carcinoma 148

Interventions

fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Female Breast Cancer Patients × Breast × Clear all
NCT07357207 2026-01-23

VIT-BC

Izmir Biomedicine and Genome Center

Phase NA Enrolling by invitation
80 enrolled
Breast

Female Breast Cancer Patients

NCT06254066 2024-02-12

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
40 enrolled
Breast

Female Breast Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡